PSMA imaging has become a key part of prostate cancer for diagnosis, disease staging, and assessing response to therapy. In recent years, several novel PSMA-targeted radiotracers have been developed for PSMA imaging. These are more sensitive, specific, and accurate than other imaging modalities.

Join experts Jason Hafron, MD​ and David M. Schuster, MD FACR who discuss best practices for the use of PSMA PET/CT in prostate cancer, including the role of PSMA as a biomarker for prostate cancer, data on currently available and emerging PSMA radiotracers, and how best to integrate PSMA PET/CT as an imaging modality in your clinical practice.